Clinical trial • Phase II • Oncology

Abemaciclib for Stage IV lung cancer | Breast cancer

Phase II trial of Abemaciclib for Stage IV lung cancer | Breast cancer. 1 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Stage IV lung cancer | Breast cancer
Trial Stage
Phase II
Drug Modality
Small molecule | Monoclonal antibody

Key dates

Initial CTIS Submission Date
09-02-2024
First CTIS Authorization Date
20-03-2024

Eligibility

Recruits 1 Vulnerable population selected; no details on consent or assent provided in source..

Vulnerable Population
Vulnerable population selected; no details on consent or assent provided in source.

Recruitment

Recruitment Window Months
97

Geography

Total Number Of Sites
1
Total Number Of Participants
1

Belgium

Earliest CTIS Part Ii Submission Date
19-02-2024
Latest Decision Or Authorization Date
14-11-2024
Processing Time Days
269
Number Of Sites
1
Number Of Participants
1

Sites

Site Name
Centre hospitalier universitaire de Liege
Department Name
Oncology
Contact Person Name
Aurélie Poncin
Contact Person Email
aponcin@chuliege.be

Sponsor

Primary sponsor

Full Name
Eli Lilly & Co.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
Abemaciclib
Active Substance
Abemaciclib
Modality
Small molecule
Routes Of Administration
Oral
Route
Oral
Investigational Product Name
Pembrolizumab
Active Substance
Pembrolizumab
Modality
Monoclonal antibody
Routes Of Administration
Intravenous
Route
Intravenous
Combination Treatment
Yes

Related trials

Other published trials that may interest you.